Your browser doesn't support javascript.
loading
Advances of Targeted Therapy for Acute Myeloid Leukemia--Review / 中国实验血液学杂志
Journal of Experimental Hematology ; (6): 1252-1256, 2023.
Article en Zh | WPRIM | ID: wpr-1009982
Biblioteca responsable: WPRO
ABSTRACT
Acute myeloid leukemia (AML) has highly heterogeneous clinical manifestations and poor prognosis, and traditional chemotherapy is the main treatment. In recent years, with the in-depth development of next-generation sequencing technology, the treatment of AML is gradually exploring the precise targeted therapy in the direction of molecular biology and immunophenotype. The advent of various small-molecule inhibitors and immune-targeted drugs has brought hope to patients who cannot tolerate intensive chemotherapy or with relapsed/refractory AML. Compared with traditional chemotherapy, targeted therapy has the advantages of significant curative effect and fewer adverse effects. This article reviews the latest research progress of targeted drug therapy for AML.
Asunto(s)
Palabras clave
Texto completo: 1 Índice: WPRIM Asunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Inmunoterapia Adoptiva / Inmunoterapia Límite: Humans Idioma: Zh Revista: Journal of Experimental Hematology Año: 2023 Tipo del documento: Article
Texto completo: 1 Índice: WPRIM Asunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Inmunoterapia Adoptiva / Inmunoterapia Límite: Humans Idioma: Zh Revista: Journal of Experimental Hematology Año: 2023 Tipo del documento: Article